XL413 is a selective inhibitor of cell division cycle 7 (CDC7) kinase, making it a valuable compound in cancer research. It works by blocking DNA replication initiation in cancer cells, leading to replication stress and activation of apoptotic pathways. This compound shows potential in targeting tumor cells with high proliferative rates, particularly in cancers with dysregulated cell cycle pathways such as certain types of breast, colon, and lung cancers. Due to its mechanism, XL413 is often studied in combination with other chemotherapeutic agents or DNA-damaging therapies to enhance anti-tumor efficacy. It is primarily used in preclinical studies to evaluate CDC7 inhibition as a therapeutic strategy in oncology.